CYB001 to evaluate as a potential treatment for Major Depressive Disorder

Cybin has received approval from the Institutional Review Board (IRB) at the University of the West Indies Hospital in Jamaica for a Phase II trial of its psilocybin formulation, CYB001, to treat major depressive disorder (MDD).

This Phase II trial will assess Cybin’s sublingual psilocybin formulation versus a 25mg psilocybin capsule. A Phase IIa study will enrol 40 patients to determine the bio-equivalent dose of CYB001 when compared to a 25mg capsule.

Topic Depression
Country Jamaica
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Cybin
Cybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.